---
document_datetime: 2025-10-22 10:49:33
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/amsparity-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: amsparity-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.8889426
conversion_datetime: 2025-12-21 22:59:04.035984
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Amsparity

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type II /  | This was an application for a group of | 16/10/2025                          |                                             | Annex II and                     | Section A of Annex II is updated to include the |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000289586   | variations.   | PL   |
|---------------------|---------------|------|

<div style=\"page-break-after: always\"></div>

|                                          | - B.II.e.3.b Other changes to a test procedure (including replacement or addition) - Accepted B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted                                                                                                                                                                                                                                                                                                               |            |     |                 |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| Variation type IA_IN / EMA/VR/0000295091 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                                                                                                                                                                                      | 05/09/2025 |     | Annex II and PL |
| Variation type IB / EMA/VR/0000278949    | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to update the RMP by removing the missing information \"Long Term Safety Information in the Treatment of Children with Uveitis\" and change the missing information \"Episodic treatment in Ps, UC and JIA\" to \"Episodic treatment in UC\" from the approved RMP in order to align the RMP with the current parent product (Humira) RMP. | 20/08/2025 | N/A |                 |